Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (181-190 of 261) with videos related to

Pageof 27
Sort By:
Cancers|February 25, 2023
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer ModelsNisha Gupta, Hiroki Ochiai, Yoshinori Hoshino, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
NPJ Precision Oncology|October 31, 2018
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapyTheodore S Hong, Clemens Grassberger, Beow Y Yeap, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Oncotarget|April 23, 2021
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenibYehia I Mohamed, Sunyoung Lee, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Pageof 27

Showing results (181-190 of 261) with videos related to

Sort By:
Pageof 27
Cancers|February 25, 2023
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer ModelsNisha Gupta, Hiroki Ochiai, Yoshinori Hoshino, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
NPJ Precision Oncology|October 31, 2018
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapyTheodore S Hong, Clemens Grassberger, Beow Y Yeap, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Oncotarget|April 23, 2021
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenibYehia I Mohamed, Sunyoung Lee, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Pageof 27